You are here

Article Text

Article menu
Download PDFPDF
Treatment
Review: addition of salmeterol leads to improved lung function and fewer exacerbations in symptomatic asthma

https://doi.org/10.1136/ebn.4.1.15

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Shrewsbury S, Pyke S, Britton M.Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).BMJ2000 May 20;320:1368–73OpenUrlAbstract/FREE Full Text

    QUESTION: In patients with symptomatic asthma who are currently taking inhaled steroids, does adding salmeterol improve lung function and reduce symptoms and exacerbations compared with increasing the dose of inhaled corticosteroids?

    Data sources

    Studies were identified by searching EMBASE/Excerpta Medica, Medline, and GlaxoWellcome databases (1985 to Sept 1999).

    Study selection

    Studies were selected if they were randomised, double blind, controlled trials comparing the addition of salmeterol to the current dose of inhaled steroid with an increased dose (at least doubling) of the current inhaled steroid for ≥12 weeks in adolescents and adults with symptomatic asthma.

    Data extraction

    Data were extracted on patient characteristics; treatment type, dose, and duration; and outcome measures based on the intention to treat …

    View Full Text

    Footnotes

    • Source of funding: no external funding.

    • For correspondence: Dr S Shrewsbury, Respiratory Clinical Development, GlaxoWellcome Research & Development, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, USA. Fax +1 919 483 8835. sbs40926{at}glaxowellcome.com